Our data indicate that ATG12-deficient tumors are incapable of maintaining intracellular L-glutamine levels and therefore cannot support a significant hypoxic fraction (Figure 1F), which results in improved treatment response in HNSCC (Figures 2, 3, and 4). Here, ATG12 is linked to head and neck squamous cell carcinoma.